Patents by Inventor Chae-Seo Rhee

Chae-Seo Rhee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11642015
    Abstract: A sinus entering endoscope according to an embodiment of the present invention comprises: a body including a plurality of operation parts; an insertion part extending from the front end of the body to be inserted into the sinus through the nasal cavity, and having at least one working channel; and an applicator load part which is disposed in the body and on which a plurality of applicators which can selectively enter through the working channel can be mounted.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: May 9, 2023
    Assignee: SEOUL NATIONAL UNIVERSITY HOSPITAL
    Inventors: Chae Seo Rhee, Sung Woo Cho
  • Publication number: 20210076925
    Abstract: A sinus entering endos cope according to an embodiment of the present invention comprises: a body including a plurality of operation parts; an insertion part extending from the front end of the body to be inserted into the sinus through the nasal cavity, and having at least one working channel; and an applicator rod part which is disposed in the body and on which a plurality of applicators which can selectively enter through the working channel can be mounted.
    Type: Application
    Filed: February 25, 2019
    Publication date: March 18, 2021
    Inventors: Chae Seo RHEE, Sung Woo CHO
  • Publication number: 20160124002
    Abstract: The present invention provides a composition, kit, and method for detecting hypoxia or diagnosing hypoxia-related diseases, the composition containing a material for detecting arachidonic acid and a derivative thereof. The composition, kit, and method according to the present invention can conveniently and promptly detect hypoxia through the detection of a biomarker in a biological sample, and thus can be useful in the prevention or early diagnose of diseases caused by hypoxia, the determination of the severity of diseases and therapeutic effects, tracking of diseases, or the like.
    Type: Application
    Filed: April 29, 2014
    Publication date: May 5, 2016
    Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Jong Wan PARK, Hyun Woo SHIN, Joo-Youn CHO, Chae-Seo RHEE, Il-Hee HONG
  • Patent number: 7713526
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: May 11, 2010
    Assignee: The Regents of the University of California
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson
  • Patent number: 7682607
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: March 23, 2010
    Assignee: The Regents of the University of California
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson
  • Publication number: 20040203003
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Application
    Filed: March 5, 2004
    Publication date: October 14, 2004
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M Leoni, Maripat Corr, Dennis A Carson
  • Publication number: 20030165500
    Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
    Type: Application
    Filed: November 1, 2002
    Publication date: September 4, 2003
    Applicant: REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson
  • Publication number: 20030044409
    Abstract: This invention is in the field of immunology. More specifically, it relates to compositions and methods for identifying, treating and preventing cancer by targeting the extracellular domains of the frizzled receptor family of proteins.
    Type: Application
    Filed: May 1, 2001
    Publication date: March 6, 2003
    Inventors: Dennis A. Carson, Maripat Corr, Chae-Seo Rhee, Lorenzo M. Leoni, Malini Sen